耐甲氧西林金黄色葡萄球菌（MRSA）呈现多重广泛耐药，临床感染危害严重，但目前尚未成功研制的有效MRSA疫苗。肠毒素Ｂ（SEB）是MRSA的主要毒力因子，其重组突变体可诱导有效的免疫保护，是MRSA疫苗的重要候选抗原。我们前期实验发现：SEB的抗体依赖的免疫保护作用在不同佐剂辅助下存在差异，弗氏佐剂辅助下的免疫保护效果优于铝盐佐剂，该保护性应答的具体分子基础和作用机制尚不明确。因此，本项目拟用抗体免疫优势应答分析技术，对SEB抗原中免疫优势应答的Ｂ细胞表位进行筛选与鉴定，并通过体内外实验阐明其免疫保护作用和应答机制，对不同佐剂辅助下抗体依赖的抗原免疫保护效果差异提出新的解释，为基于SEB抗原的MRSA疫苗设计策略的优化提供候选分子和理论依据。

Methicillin-resistant Staphylococcus aureus (MRSA) show multiple drug-resistant,serious clinical infection and damage, but at present there is no effective MRSA vaccine that has been successfully developed. Staphylococcal enterotoxin B (SEB) is a major virulence factor of MRSA, and its recombinant mutant can induce effective immune protection.Therefore,it is an important candidate antigen of MRSA vaccine.Our previous study showed that:antibody dependent protective immune effects of SEB show significant difference when assisted with different adjuvants. Effects assisted with Freund's adjuvant adjuvant is better than that with CFA aluminum salt adjuvants.The specific molecular basis and mechanism of the protective response is still not clear. Therefore,this project aims to screen and identify the B cell immunodominant epitopes of SEB by the technology of immunodominant antibody response analysis,and to clarify the immune protective effect and response mechanism of SEB by in vivo and in vitro experiments,then finally put forward a new explanation of the different antibody dependent protective effects of antigen when assisted with different adjuvants,and therefore provide candidate molecule and the theory basis to optimize MRSA vaccine design strategy based on the SEB antigen.